Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

Biotechnology

Health & Wellness

Health Care

Pharmaceutical

Amolyt Pharma

Thierry Abribat

Niccole Larsen, PhD

michel ovize

Blandine WEISS

Taha Ould Rouis, MD

Caroline Robo (Fesquet)

Patrick Loustau

Michael Culler

Lou Arcudi

Laetitia Ouafki

Héloïse Boullet

Guillaume Ravel, PharmD, PhD, DABT

Delphine Martinez

Damien Aumaille

Clémentine Chalmey

Aurélie MILLERAT

The Medical Affairs and Development team at Amolyt Pharma spearheads the clinical advancement and medical strategy of peptide treatments for rare endocrine and metabolic disorders. They ensure that all preclinical and clinical data align with regulatory standards, engage with global medical communities to communicate scientific insights, and drive initiatives to optimize patient outcomes and treatment adoption.

Medical Affairs and Development

Clinical Management Team

Leadership Team

CMC Team

Medical Affairs and Development

About

Team members

Other teams at Amolyt Pharma

Clinical Management Team

Leadership Team

CMC Team